Orexo AB
STO:ORX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Orexo AB
Income from Continuing Operations
Orexo AB
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Orexo AB
STO:ORX
|
Income from Continuing Operations
-kr403.3m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-7%
|
|
|
Camurus AB
STO:CAMX
|
Income from Continuing Operations
kr735.6m
|
CAGR 3-Years
137%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
E
|
Enzymatica AB (publ)
STO:ENZY
|
Income from Continuing Operations
-kr51.9m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-2%
|
|
|
S
|
Swedencare AB (publ)
STO:SECARE
|
Income from Continuing Operations
kr55.5m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
11%
|
CAGR 10-Years
24%
|
|
|
I
|
Infant Bacterial Therapeutics AB
STO:IBT B
|
Income from Continuing Operations
-kr65.2m
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
I
|
InDex Pharmaceuticals Holding AB
STO:FLERIE
|
Income from Continuing Operations
-kr756.9m
|
CAGR 3-Years
-96%
|
CAGR 5-Years
-67%
|
CAGR 10-Years
N/A
|
|
Orexo AB
Glance View
Orexo AB engages in the development of pharmaceuticals based on innovative drug delivery technologies. The company is headquartered in Uppsala, Uppsala and currently employs 121 full-time employees. The company went IPO on 2005-11-09. The company focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The firm has four commercialized products, several projects developed in partnership, as well as three development programs. The firm's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The firm operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
See Also
What is Orexo AB's Income from Continuing Operations?
Income from Continuing Operations
-403.3m
SEK
Based on the financial report for Dec 31, 2025, Orexo AB's Income from Continuing Operations amounts to -403.3m SEK.
What is Orexo AB's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-7%
Over the last year, the Income from Continuing Operations growth was 16%. The average annual Income from Continuing Operations growth rates for Orexo AB have been -31% over the past three years , -37% over the past five years , and -7% over the past ten years .
